Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports strong growth in first quarter of 2015

Roche reports strong growth in first quarter of 2015

22nd April 2015

Roche has announced its financial results for the first quarter of 2015, during which it achieved a first-quarter sales total of 11.83 billion Swiss francs (8.27 billion pounds).

This represented a year-on-year increase of five percent on a constant currency basis, with its pharmaceuticals division growing by four percent on the back of strong sales of oncology products like Avastin and MabThera/Rituxan, as well as immunology offerings such as Actemra/RoActemra and Xolair.

Meanwhile, its diagnostics division sales were up by six percent, with a good performance across all business units. This allowed Roche to confirm its full-year forecast of low to mid-single digit sales growth.

Key highlights of the quarter included the receipt of a breakthrough medicine designation for its cancer immunotherapy medicine anti-PDL1 in the US, as well as strong demand for its idiopathic pulmonary fibrosis drug Esbriet and the creation of a strategic partnership with Foundation Medicine.

Severin Schwan, Roche's chief executive officer, said: "We started the year with strong growth and good uptake of new products."ADNFCR-8000103-ID-801784561-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.